Cashu Finance
  • Terminal
  • Stocks
  • Spotlight
  • Research
Log inSign Up
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. PLRZ

Market Cap: $12.36M

PL

Polyrizon Ltd.

PLRZ
NASDAQ (NASDAQ Global Market)USD
Purchase PLRZ
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutivePatentsEarnings Surprise
Cashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

–
USD
–(–)

Open

$14.00

Prev. Close

$11.23

High

$15.35

Low

$13.68

Company Profile

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

CEOTomer Izraeli
SectorHealthcare
IndustryBiotechnology
Employees6
IPO DateOct 29, 2024
ExchangeNASDAQ
Exchange NameNASDAQ Global Market
CurrencyUSD
Headquarters & Contact
Address5 Ha-Tidhar Street
City / State / ZIPRa'anana, TA, 4321545
CountryIsrael
Phone972 9 374 0120
Websitehttps://www.polyrizon-biotech.com

Recently from Cashu